Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EDNRB | P24530 | 1/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.45 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749573 | 0.89 | PTGDR2 (0.65) | PTGDR2TSHRHTTEDNRBEDNRA | |
| SCHEMBL2449413 | 0.89 | PTGDR2 (0.57) | PTGDR2LIMK2 | |
| SCHEMBL2446963 | 0.85 | PTGDR2 (0.60) | PTGDR2 | |
| SCHEMBL2449138 | 0.85 | PTGDR2 (0.58) | PTGDR2 | |
| SCHEMBL6751658 | 0.84 | PTGDR2 (0.53) | PTGDR2TSHRHTT | |
| SCHEMBL6751910 | 0.82 | PTGDR2 (0.57) | PTGDR2TSHRHTTEDNRBEDNRA | |
| SCHEMBL2444500 | 0.80 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL2442799 | 0.80 | PTGDR2 (0.70) | PTGDR2 | |
| SCHEMBL4376658 | 0.78 | PTGDR2 (0.66) | PTGDR2TSHR | |
| SCHEMBL6749580 | 0.76 | PTGDR2 (0.55) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796280-B2 | 2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors | Merck Serono, S.A. (CH) | 2014-08-05 | — | — | US | disclosed |
| EP-1871374-B1 | 2,3 SUBSTITUTED PYRAZINE SULFONAMIDES AS INHIBITORS OF CRTH2 | MERCK SERONO SA (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-20090054447-A1 | 2,3 Substituted Pyrazine Sulfonamides as Inhibitors of CRTH2 | LABORATOIRES SERONO S.A. (CH) | 2009-02-26 | — | — | US | disclosed |
| EP-1871374-A2 | 2,3 SUBSTITUTED PYRAZINE SULFONAMIDES AS INHIBITORS OF CRTH2 | Laboratoires Serono SA (CH) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111560-A2 | 2,3 SUBSTITUTED PYRAZINE SULFONAMIDES AS INHIBITORS OF CRTH2 | LABORATOIRES SERONO S.A. (CH) | 2006-10-26 | — | — | WO | disclosed |
| WO-2004058265-A1 | COMPOUND LIBRARIES OF 2,3-SUBSTITUTED PYRAZINE DERIVATIVES CAPABLE OF BINDING TO G-PROTEIN COUPLED RECEPTORS | BIOFOCUS PLC (GB) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054447-A1 | 2,3 Substituted Pyrazine Sulfonamides as Inhibitors of CRTH2 | HRH2, HRH1, HRH4 | PTGDR2 84/4885TSHR 2446/4885HTT 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.